2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Vobramitamab duocarmazine

Vobramitamab duocarmazine  (Synonyms: AEX4089DC1; MGC018)

Cat. No.: HY-145636
Handling Instructions Technical Support

Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity.

For research use only. We do not sell to patients.

Vobramitamab duocarmazine

Vobramitamab duocarmazine Chemical Structure

CAS No. : 2490556-51-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Vobramitamab duocarmazine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity[1].

In Vitro

Vobramitamab duocarmazine (MGC018; for 7 days) exhibits cytotoxicity toward B7-H3-positive human tumor cell lines, including MDA-MB-468, A375.S2, PA-1, Calu-6, NCI-H1703, Hs700T, LN-229, and SW48 cancer cells, with IC50 values range of 181-1447 pM. Vobramitamab duocarmazine exhibited bystander killing of target-negative tumor cells when cocultured with B7-H3-positive tumor cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vobramitamab duocarmazine Related Antibodies
In Vivo

Vobramitamab duocarmazine (MGC018; 3-6 mg/kg; i.v; single-dose) leads to a dose-dependent decrease in tumor growth of MDA-MB-468 triple-negative breast cancer xenografts[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) leads to a rapid tumor regression, with a 98% reduction in tumor volume in a triple-negative breast cancer patient-derived xenograft (PDX) model[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in the PA-1 ovarian cancer xenografts. A reduction in tumor volume of 89%, 91%, and 43%, is observed following treatment with Vobramitamab duocarmazine at 10, 6, and 3 mg/kg, respectively[1].
Vobramitamab duocarmazine (MGC018; 1-3 mg/kg; i.v; single-dose) shows antitumor activity in A375.S2 melanoma xenografts[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in Calu-6 lung cancer xenografts. A reduction in tumor volume of 91%, 84%, and 72% is observed following treatment with Vobramitamab duocarmazine at 10 mg/kg, 6 mg/kg, and 3 mg/kg, respectively[1].
Vobramitamab duocarmazine (MGC018; 3 mg/kg; QW×3 or Q2W×2; i.v) shows antitumor activity toward patient-derived xenograft models of prostate, and head and neck cancer displaying heterogeneous expression of B7-H3[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CD-1 nude (homozygous) mice (Crl:CD1-Foxn1nu) and female SCID/CES1c KO mice (5-7 weeks old) injected with MDA-MB-468 cells[1]
Dosage: 3 mg/kg, 6 mg/kg
Administration: Tail vein injection; a single-dose
Result: Led to a dose-dependent decrease in tumor growth of MDA-MB-468 triple-negative breast cancer xenografts.
Animal Model: Female Athymic Nude-Foxn1nu mice (triple-negative breast cancer models)[1]
Dosage: 3 mg/kg
Administration: Tail vein injection; once a week; for 2 weeks
Result: Led to a rapid tumor regression, with a 98% reduction in tumor volume.
CAS No.
SMILES

[Vobramitamab duocarmazine]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vobramitamab duocarmazine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vobramitamab duocarmazine2490556-51-7AEX4089DC1 MGC018MGC018MGC 018MGC-018Antibody-Drug Conjugates (ADCs)Antibody-Drug ConjugateshumanizedADCB7-H3CD276antineoplastic activityVc-seco-DUBAInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vobramitamab duocarmazine
Cat. No.:
HY-145636
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.